Fusobacterium nucleatum and T cells in colorectal carcinoma

Kosuke Mima, Yasutaka Sukawa, Reiko Nishihara, Zhi Rong Qian, Mai Yamauchi, Kentaro Inamura, Sun A. Kim, Atsuhiro Masuda, Jonathan A. Nowak, Katsuhiko Nosho, Aleksandar D. Kostic, Marios Giannakis, Hideo Watanabe, Susan Bullman, Danny A. Milner, Curtis C. Harris, Edward Giovannucci, Levi A. Garraway, Gordon J. Freeman, Glenn DranoffAndrew T. Chan, Wendy S. Garrett, Curtis Huttenhower, Charles S. Fuchs, Shuji Ogino

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Importance: Evidence indicates a complex link between gut microbiome, immunity, and intestinal tumorigenesis. To target the microbiota and immunity for colorectal cancer prevention and therapy, a better understanding of the relationship between microorganisms and immune cells in the tumor microenvironment is needed. Experimental evidence suggests that Fusobacterium nucleatum may promote colonic neoplasia development by downregulating antitumor T cell-mediated adaptive immunity. Objective: To test the hypothesis that a greater amount of F nucleatum in colorectal carcinoma tissue is associated with a lower density of T cells in tumor tissue. Design, Setting, and Participants: A cross-sectional analysiswas conducted on 598 rectal and colon carcinoma cases in 2 US nationwide prospective cohort studies with follow-up through 2006, the Nurses' Health Study (participants enrolled in 1976) and the Health Professionals Follow-up Study (participants enrolled in 1986). Tissue collection and processing were performed from 2002 through 2008, and immunity assessment, 2008 through 2009. From 2013 through 2014, the amount of F nucleatum in colorectal carcinoma tissue was measured by quantitative polymerase chain reaction assay; we equally dichotomized positive cases (high vs low). Multivariable ordinal logistic regression analysis was conducted in 2014 to assess associations of the amount of F nucleatum with densities (quartiles) of T cells in tumor tissue, controlling for clinical and tumor molecular features, including microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide element-1 (LINE-1)methylation, and KRAS, BRAF, and PIK3CA mutation status. We adjusted the 2-sided α level to .013 for multiple hypothesis testing. Main Outcomes and Measures: Densities of CD3+, CD8+, CD45RO (protein tyrosine phosphatase receptor type C [PTPRC])+, and FOXP3+ T cells in tumor tissue, determined by means of tissue microarray immunohistochemical analysis and computer-assisted image analysis. Results: F nucleatum was detected in colorectal carcinoma tissue in 76 (13%) of 598 cases. Compared with F nucleatum-negative cases, F nucleatum-high cases were inversely associated with the density of CD3+ T cells (for a unit increase in quartile categories of CD3+ T cells as an outcome: multivariable odds ratio, 0.47 [95%CI, 0.26-0.87]; P for trend = .006). The amount of F nucleatum was not significantly associated with the density of CD8+, CD45RO+, or FOXP3+ T cells (P for trend = .24, .88, and .014, respectively). Conclusions and Relevance: The amount of tissue F nucleatum is inversely associated with CD3+ T-cell density in colorectal carcinoma tissue. On validation, our human population data may provide an impetus for further investigations on potential interactive roles of Fusobacterium and host immunity in colon carcinogenesis.

Original languageEnglish
Pages (from-to)653-661
Number of pages9
JournalJAMA oncology
Volume1
Issue number5
DOIs
Publication statusPublished - 2015 Aug 1
Externally publishedYes

Fingerprint

Fusobacterium nucleatum
Colorectal Neoplasms
T-Lymphocytes
Immunity
Neoplasms
Colon
Carcinogenesis
Long Interspersed Nucleotide Elements
Tissue Array Analysis
Fusobacterium
CD45 Antigens
Microsatellite Instability
CpG Islands
Tumor Microenvironment
Computer-Assisted Image Processing
Microbiota
Health
Adaptive Immunity
Cellular Immunity
Methylation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mima, K., Sukawa, Y., Nishihara, R., Qian, Z. R., Yamauchi, M., Inamura, K., ... Ogino, S. (2015). Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA oncology, 1(5), 653-661. https://doi.org/10.1001/jamaoncol.2015.1377

Fusobacterium nucleatum and T cells in colorectal carcinoma. / Mima, Kosuke; Sukawa, Yasutaka; Nishihara, Reiko; Qian, Zhi Rong; Yamauchi, Mai; Inamura, Kentaro; Kim, Sun A.; Masuda, Atsuhiro; Nowak, Jonathan A.; Nosho, Katsuhiko; Kostic, Aleksandar D.; Giannakis, Marios; Watanabe, Hideo; Bullman, Susan; Milner, Danny A.; Harris, Curtis C.; Giovannucci, Edward; Garraway, Levi A.; Freeman, Gordon J.; Dranoff, Glenn; Chan, Andrew T.; Garrett, Wendy S.; Huttenhower, Curtis; Fuchs, Charles S.; Ogino, Shuji.

In: JAMA oncology, Vol. 1, No. 5, 01.08.2015, p. 653-661.

Research output: Contribution to journalArticle

Mima, K, Sukawa, Y, Nishihara, R, Qian, ZR, Yamauchi, M, Inamura, K, Kim, SA, Masuda, A, Nowak, JA, Nosho, K, Kostic, AD, Giannakis, M, Watanabe, H, Bullman, S, Milner, DA, Harris, CC, Giovannucci, E, Garraway, LA, Freeman, GJ, Dranoff, G, Chan, AT, Garrett, WS, Huttenhower, C, Fuchs, CS & Ogino, S 2015, 'Fusobacterium nucleatum and T cells in colorectal carcinoma', JAMA oncology, vol. 1, no. 5, pp. 653-661. https://doi.org/10.1001/jamaoncol.2015.1377
Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA oncology. 2015 Aug 1;1(5):653-661. https://doi.org/10.1001/jamaoncol.2015.1377
Mima, Kosuke ; Sukawa, Yasutaka ; Nishihara, Reiko ; Qian, Zhi Rong ; Yamauchi, Mai ; Inamura, Kentaro ; Kim, Sun A. ; Masuda, Atsuhiro ; Nowak, Jonathan A. ; Nosho, Katsuhiko ; Kostic, Aleksandar D. ; Giannakis, Marios ; Watanabe, Hideo ; Bullman, Susan ; Milner, Danny A. ; Harris, Curtis C. ; Giovannucci, Edward ; Garraway, Levi A. ; Freeman, Gordon J. ; Dranoff, Glenn ; Chan, Andrew T. ; Garrett, Wendy S. ; Huttenhower, Curtis ; Fuchs, Charles S. ; Ogino, Shuji. / Fusobacterium nucleatum and T cells in colorectal carcinoma. In: JAMA oncology. 2015 ; Vol. 1, No. 5. pp. 653-661.
@article{7bee120d1a4147a480bc3b7834a550c1,
title = "Fusobacterium nucleatum and T cells in colorectal carcinoma",
abstract = "Importance: Evidence indicates a complex link between gut microbiome, immunity, and intestinal tumorigenesis. To target the microbiota and immunity for colorectal cancer prevention and therapy, a better understanding of the relationship between microorganisms and immune cells in the tumor microenvironment is needed. Experimental evidence suggests that Fusobacterium nucleatum may promote colonic neoplasia development by downregulating antitumor T cell-mediated adaptive immunity. Objective: To test the hypothesis that a greater amount of F nucleatum in colorectal carcinoma tissue is associated with a lower density of T cells in tumor tissue. Design, Setting, and Participants: A cross-sectional analysiswas conducted on 598 rectal and colon carcinoma cases in 2 US nationwide prospective cohort studies with follow-up through 2006, the Nurses' Health Study (participants enrolled in 1976) and the Health Professionals Follow-up Study (participants enrolled in 1986). Tissue collection and processing were performed from 2002 through 2008, and immunity assessment, 2008 through 2009. From 2013 through 2014, the amount of F nucleatum in colorectal carcinoma tissue was measured by quantitative polymerase chain reaction assay; we equally dichotomized positive cases (high vs low). Multivariable ordinal logistic regression analysis was conducted in 2014 to assess associations of the amount of F nucleatum with densities (quartiles) of T cells in tumor tissue, controlling for clinical and tumor molecular features, including microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide element-1 (LINE-1)methylation, and KRAS, BRAF, and PIK3CA mutation status. We adjusted the 2-sided α level to .013 for multiple hypothesis testing. Main Outcomes and Measures: Densities of CD3+, CD8+, CD45RO (protein tyrosine phosphatase receptor type C [PTPRC])+, and FOXP3+ T cells in tumor tissue, determined by means of tissue microarray immunohistochemical analysis and computer-assisted image analysis. Results: F nucleatum was detected in colorectal carcinoma tissue in 76 (13{\%}) of 598 cases. Compared with F nucleatum-negative cases, F nucleatum-high cases were inversely associated with the density of CD3+ T cells (for a unit increase in quartile categories of CD3+ T cells as an outcome: multivariable odds ratio, 0.47 [95{\%}CI, 0.26-0.87]; P for trend = .006). The amount of F nucleatum was not significantly associated with the density of CD8+, CD45RO+, or FOXP3+ T cells (P for trend = .24, .88, and .014, respectively). Conclusions and Relevance: The amount of tissue F nucleatum is inversely associated with CD3+ T-cell density in colorectal carcinoma tissue. On validation, our human population data may provide an impetus for further investigations on potential interactive roles of Fusobacterium and host immunity in colon carcinogenesis.",
author = "Kosuke Mima and Yasutaka Sukawa and Reiko Nishihara and Qian, {Zhi Rong} and Mai Yamauchi and Kentaro Inamura and Kim, {Sun A.} and Atsuhiro Masuda and Nowak, {Jonathan A.} and Katsuhiko Nosho and Kostic, {Aleksandar D.} and Marios Giannakis and Hideo Watanabe and Susan Bullman and Milner, {Danny A.} and Harris, {Curtis C.} and Edward Giovannucci and Garraway, {Levi A.} and Freeman, {Gordon J.} and Glenn Dranoff and Chan, {Andrew T.} and Garrett, {Wendy S.} and Curtis Huttenhower and Fuchs, {Charles S.} and Shuji Ogino",
year = "2015",
month = "8",
day = "1",
doi = "10.1001/jamaoncol.2015.1377",
language = "English",
volume = "1",
pages = "653--661",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Fusobacterium nucleatum and T cells in colorectal carcinoma

AU - Mima, Kosuke

AU - Sukawa, Yasutaka

AU - Nishihara, Reiko

AU - Qian, Zhi Rong

AU - Yamauchi, Mai

AU - Inamura, Kentaro

AU - Kim, Sun A.

AU - Masuda, Atsuhiro

AU - Nowak, Jonathan A.

AU - Nosho, Katsuhiko

AU - Kostic, Aleksandar D.

AU - Giannakis, Marios

AU - Watanabe, Hideo

AU - Bullman, Susan

AU - Milner, Danny A.

AU - Harris, Curtis C.

AU - Giovannucci, Edward

AU - Garraway, Levi A.

AU - Freeman, Gordon J.

AU - Dranoff, Glenn

AU - Chan, Andrew T.

AU - Garrett, Wendy S.

AU - Huttenhower, Curtis

AU - Fuchs, Charles S.

AU - Ogino, Shuji

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Importance: Evidence indicates a complex link between gut microbiome, immunity, and intestinal tumorigenesis. To target the microbiota and immunity for colorectal cancer prevention and therapy, a better understanding of the relationship between microorganisms and immune cells in the tumor microenvironment is needed. Experimental evidence suggests that Fusobacterium nucleatum may promote colonic neoplasia development by downregulating antitumor T cell-mediated adaptive immunity. Objective: To test the hypothesis that a greater amount of F nucleatum in colorectal carcinoma tissue is associated with a lower density of T cells in tumor tissue. Design, Setting, and Participants: A cross-sectional analysiswas conducted on 598 rectal and colon carcinoma cases in 2 US nationwide prospective cohort studies with follow-up through 2006, the Nurses' Health Study (participants enrolled in 1976) and the Health Professionals Follow-up Study (participants enrolled in 1986). Tissue collection and processing were performed from 2002 through 2008, and immunity assessment, 2008 through 2009. From 2013 through 2014, the amount of F nucleatum in colorectal carcinoma tissue was measured by quantitative polymerase chain reaction assay; we equally dichotomized positive cases (high vs low). Multivariable ordinal logistic regression analysis was conducted in 2014 to assess associations of the amount of F nucleatum with densities (quartiles) of T cells in tumor tissue, controlling for clinical and tumor molecular features, including microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide element-1 (LINE-1)methylation, and KRAS, BRAF, and PIK3CA mutation status. We adjusted the 2-sided α level to .013 for multiple hypothesis testing. Main Outcomes and Measures: Densities of CD3+, CD8+, CD45RO (protein tyrosine phosphatase receptor type C [PTPRC])+, and FOXP3+ T cells in tumor tissue, determined by means of tissue microarray immunohistochemical analysis and computer-assisted image analysis. Results: F nucleatum was detected in colorectal carcinoma tissue in 76 (13%) of 598 cases. Compared with F nucleatum-negative cases, F nucleatum-high cases were inversely associated with the density of CD3+ T cells (for a unit increase in quartile categories of CD3+ T cells as an outcome: multivariable odds ratio, 0.47 [95%CI, 0.26-0.87]; P for trend = .006). The amount of F nucleatum was not significantly associated with the density of CD8+, CD45RO+, or FOXP3+ T cells (P for trend = .24, .88, and .014, respectively). Conclusions and Relevance: The amount of tissue F nucleatum is inversely associated with CD3+ T-cell density in colorectal carcinoma tissue. On validation, our human population data may provide an impetus for further investigations on potential interactive roles of Fusobacterium and host immunity in colon carcinogenesis.

AB - Importance: Evidence indicates a complex link between gut microbiome, immunity, and intestinal tumorigenesis. To target the microbiota and immunity for colorectal cancer prevention and therapy, a better understanding of the relationship between microorganisms and immune cells in the tumor microenvironment is needed. Experimental evidence suggests that Fusobacterium nucleatum may promote colonic neoplasia development by downregulating antitumor T cell-mediated adaptive immunity. Objective: To test the hypothesis that a greater amount of F nucleatum in colorectal carcinoma tissue is associated with a lower density of T cells in tumor tissue. Design, Setting, and Participants: A cross-sectional analysiswas conducted on 598 rectal and colon carcinoma cases in 2 US nationwide prospective cohort studies with follow-up through 2006, the Nurses' Health Study (participants enrolled in 1976) and the Health Professionals Follow-up Study (participants enrolled in 1986). Tissue collection and processing were performed from 2002 through 2008, and immunity assessment, 2008 through 2009. From 2013 through 2014, the amount of F nucleatum in colorectal carcinoma tissue was measured by quantitative polymerase chain reaction assay; we equally dichotomized positive cases (high vs low). Multivariable ordinal logistic regression analysis was conducted in 2014 to assess associations of the amount of F nucleatum with densities (quartiles) of T cells in tumor tissue, controlling for clinical and tumor molecular features, including microsatellite instability, CpG island methylator phenotype, long interspersed nucleotide element-1 (LINE-1)methylation, and KRAS, BRAF, and PIK3CA mutation status. We adjusted the 2-sided α level to .013 for multiple hypothesis testing. Main Outcomes and Measures: Densities of CD3+, CD8+, CD45RO (protein tyrosine phosphatase receptor type C [PTPRC])+, and FOXP3+ T cells in tumor tissue, determined by means of tissue microarray immunohistochemical analysis and computer-assisted image analysis. Results: F nucleatum was detected in colorectal carcinoma tissue in 76 (13%) of 598 cases. Compared with F nucleatum-negative cases, F nucleatum-high cases were inversely associated with the density of CD3+ T cells (for a unit increase in quartile categories of CD3+ T cells as an outcome: multivariable odds ratio, 0.47 [95%CI, 0.26-0.87]; P for trend = .006). The amount of F nucleatum was not significantly associated with the density of CD8+, CD45RO+, or FOXP3+ T cells (P for trend = .24, .88, and .014, respectively). Conclusions and Relevance: The amount of tissue F nucleatum is inversely associated with CD3+ T-cell density in colorectal carcinoma tissue. On validation, our human population data may provide an impetus for further investigations on potential interactive roles of Fusobacterium and host immunity in colon carcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85010756263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010756263&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2015.1377

DO - 10.1001/jamaoncol.2015.1377

M3 - Article

C2 - 26181352

AN - SCOPUS:85010756263

VL - 1

SP - 653

EP - 661

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 5

ER -